NicholasMitsiadesMDPhD
Oncology • Sacramento, CAGenitourinary Oncology
Chief Translational Officer and Associate Director for Translational Research Comprehensive Cancer Center, UC Davis Health and Professor, Department of Internal Medicine, Division of Hematology and Oncology. E-mail: nmitsiades@ucdavis.edu
Dr. Mitsiades is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4501 X Street
Suite 3016
Sacramento, CA 95817Phone+1 916-734-3772
Summary
- Dr. Nicholas Mitsiades is a physician-scientist and clinically-trained medical oncologist and endocrinologist specialized in the treatment of endocrine malignancies, in particular prostate cancer. He is the Chief Translational Officer and Associate Director for Translational Research of the Comprehensive Cancer Center, UC Davis Health. He is a Professor in the Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health.
E-mail: nmitsiades@ucdavis.edu
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2007- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
University of AthensClass of 1995
Certifications & Licensure
CA State Medical License 2022 - 2026
TX State Medical License 2010 - 2022
NY State Medical License 2009 - 2011- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member American Society for Clinical Investigation, 2019
Clinical Trials
- S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Start of enrollment: 2011 Aug 09
- Study of Metformin With Simvastatin for Men With Prostate Carcinoma Start of enrollment: 2012 Jan 01
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
- Join now to see all
Publications & Presentations
PubMed
- Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma ce...Constantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, Robert Schlossman, Masaharu Akiyama
Oncogene. 2024-11-11 - 1 citationsLX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.Shu Ning, Cameron M Armstrong, Enming Xing, Amy R Leslie, Richard Y Gao
Cancer Research. 2024-11-04 - PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells.Zachary A Schaaf, Shu Ning, Amy R Leslie, Masuda Sharifi, Richard Y Gao
Cancer Research Communications. 2024-11-01
Press Mentions
Cancer Center Appoints New Chief Translational OfficerSeptember 16th, 2022- Tempus Unveils Its Lens Platform, Offering Unparalleled Access to One of the World’s Largest De-Identified Clinical and Molecular DatasetsMay 20th, 2021
Baylor Research Team Gets $6.3M to Study Disparities Among Minorities with Prostate, Breast CancersOctober 22nd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
